Abstract:A large number of β-adrenergic receptor (β-AR) agonists and antagonists are widely used in the treatment of cardiovascular diseases and other diseases. Nonetheless, it remains unclear whether these commonly used β-AR drugs can activate downstream β- arrestin-biased signaling pathways. The objective of this study was to investigate β-arrestin2 recruitment effects of β-AR agonists and antagonists that were commonly used in clinical practice. We used TANGO (transcriptional activation following arrestin translocation) assay to detect the β-arrestin2 recruitment by β-AR ligands in HEK293 cell line (HTLA cells) stably transfected with tetracycline transactivator protein (tTA) dependent luciferase reporter and β-arrestin2-TEV fusion gene. Upon activation of β-AR by a β-AR ligand, β-arrestin2 was recruited to the C terminus of the receptor, followed by cleavage of the G protein-coupled receptors (GPCRs) fusion protein at the TEV protease-cleavage site. The cleavage resulted in the release of tTA, which, after being transported to the nucleus, activated transcription of the luciferase reporter gene. The results showed that β-AR non-selective agonists epinephrine, noradrenaline and isoprenaline all promoted β-arrestin2 recruitment at β1-AR and β2-AR. β1-AR selective agonists dobutamine and denopamine both promoted β-arrestin2 recruitment at β1-AR. β2-AR selective agonists procaterol and salbutamol promoted β-arrestin2 recruitment at β2-AR. β-AR non-selective antagonists alprenolol and pindolol promoted β-arrestin2 recruitment at β1-AR. β1-AR selective antagonists celiprolol and bevantolol showed β-arrestin2 recruitment at β1-AR. β2-AR selective antagonists butoxamine showed β-arrestin2 recruitment at β1-AR. These results provide some clues for the potential action of β-AR drugs, and lay a foundation for the screening of β-arrestin-biased β-AR ligands.

Roles of Β-Arrestins in Signaling Pathway of AT1 Receptor

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Arrestin-biased AT1R Agonism Induces Acute Catecholamine Secretion Through TRPC3 Coupling

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

The role and mechanism of β-arrestin2 in signal transduction

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Β-Arrestin-biased AT1R Stimulation Promotes Extracellular Matrix Synthesis in Renal Fibrosis.

Β-Arrestins: Multifunctional Signaling Adaptors in Type 2 Diabetes.

Progress studing in the role of arrestins

Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics

Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.

Functional Specialization of Β-Arrestin Interactions Revealed by Proteomic Analysis

β-arrestin and β-adrenergic Receptor

Β-Arrestins As Potential Therapeutic Targets for Alzheimer’s Disease

[Ca2+](I) And Pkc-Alpha Are Involved In The Inhibitory Effects Of 1b, A Novel Nonpeptide Angiotensinii Subtype At(1) Receptor Antagonist, On Angiotensinii-Induced Vascular Contraction In Vitro

Β-Arrestin2 Recruitment by Β-Adrenergic Receptor Agonists and Antagonists

Research progress in prorenin and prorenin receptor

Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases

A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology

Mechanism of renin-angiotensin-aldosterone system inhibitors

Antihypertensive Effects of a New Angiotensin Type 1 Receptor Antagonist I B on Rats